Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib vs Sunitinib in Advanced GIST After Imatinib
NCT04633122Phase 2Completed
- Sponsor
- Zai Lab
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ripretinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Zai Lab. Primary endpoint: Progression-Free Survival at 12 months. Started Nov 2020; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04633122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633122.